Inhaled or aerosol vaccine delivery which mimics the natural route of COVID-19 infection, has attracted significant attention for the management of the disease and several clinical trials have been registered. The advent of inhalation as a potential route for vaccination of COVID-19 has a number of plusses compared to conventional administration. Nonetheless, several challenges need to be addressed.
In recent days and weeks there have been statements made about moving from a Covid-19 pandemic state to an endemic phase by the end of October 2021. The argument for this is higher adult vaccination rates that will be achieved nationwide by that time period. So we need to ask this question: Is Malaysia ready to move to an endemic phase by the end of October 2021?
The Food and Drug Administration (FDA) has recently urged people not to take Ivermectin to treat or prevent COVID-19. This warning came after it has received multiple reports of patients hospitalised after taking the medication. Science Media Centre Malaysia spoke to University Sains Malaysia's virologist and immunologist, Dr Leow Chiuan Yee to understand the potential risks of use for prevention or treatment of COVID-19.
The public needs to be vaccinated as soon as possible to reduce the transmission rate of the more dangerous COVID-19 variants, said the former Health Ministry’s National Advisor for Infectious Diseases, Datuk Dr Christopher Lee. Describing the current situation as a “race between vaccination and virus,” he said, the best way to reduce the rate of COVID-19 virus mutation in the community was through vaccination.
Orang ramai perlu divaksin secepat mungkin bagi mengurangkan kadar penularan varian-varian COVID-19 yang lebih berbahaya, demikian saranan bekas Penasihat Kebangsaan Penyakit Berjangkit Kementerian Kesihatan Malaysia, Datuk Dr Christopher Lee. Sambil menyifatkan situasi sekarang sebagai “perlumbaan antara vaksin dan virus” ujar beliau, cara terbaik untuk mengurangkan kadar mutasi virus COVID-19 dalam komuniti adalah menerusi vaksinasi.
We must not be complacent about the threat of the 5th Wave in Malaysia, especially due to the Delta variant. Our pandemic is barely under any control despite 4 weeks of a lockdown. We need to support each other and see the nation through these next few difficult months.
Recently, Malaysia has been recording an increased number of COVID-19 cases categorised by either the Variant of Concern (VOC) or Variant of Interest (VOI). VOCs or VOIs are mutant forms of the COVID virus (SARS-CoV-2), which are more virulent and infectious than its predecessor Wuhan strain. Dr Liyana explains the difference between VOI and VOCs in Malaysia.
The 3rd iteration of the Movement Control Order (MCO) has just been intensified. It is as such an opportune time for us to take cognizance of our control measures so far and in doing so realign our response measures to COVID-19. Dr Dhesi BR in his opinion piece presents six key priority areas within which said realignment must take place.
These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.
As of 12 May 2020, 4,425,094 people have been infected with SARS-CoV-2 with deaths reaching 297,723.Doctors are desperately looking for an effective drug, and there have been a number of candidates on trial; one of them, remdesivir, is probably the most exciting of all. This is the drug developed for the Ebola epidemic in 2015, but it was found to be less effective in clinical trials than in in vitro studies. Is remdesivir the panacea for COVID-19?